1. Generics Bulletin

Kabi Shares Thoughts On Interchangeability, High-Concentration Humira

Follows Launch Of US Idacio Biosimilar Last Month; Tocilizumab EMA Opinion

 
• By Dean Rudge

Fresenius Kabi’s management spoke about the company’s revamped reporting segments for the second quarter, alongside its latest endeavors in biosimilars.

A professional businessman thinking while standing on a black arrow pointing forward in grey space concept
• Source: Shutterstock

Fresenius Kabi AG has indicated that it is much more interested for now in gaining approval for a high-concentration formulation of its Idacio (adalimumab-aacf) biosimilar in the US over securing a proposed designation for interchangeability with its reference product Humira (adalimumab).

Speaking with investors as the Fresenius group presented its second-quarter financial results, Fresenius CEO Michael Sen answered “not yet” when...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business